Desmoulière A, Rubbia-Brandt L, Gabbiani G
Department of Pathology, University of Geneva, CMU, Switzerland.
Arterioscler Thromb. 1991 Mar-Apr;11(2):244-53. doi: 10.1161/01.atv.11.2.244.
Heparin inhibits arterial smooth muscle cell (SMC) proliferation in vivo and in vitro; moreover, it reinduces the expression of alpha-smooth muscle (SM) actin (an accepted marker of SMC differentiation) in SMCs of the intimal thickening that develops after experimentally induced endothelial lesions. We have investigated the effect of heparin on the proliferation and actin isoform expression in cultured rat SMCs. In the presence of 10% fetal calf serum (FCS), heparin-treated primary and passage 5 SMCs showed a decrease of proliferation and an increase of alpha-SM actin (measured by Western blots or two-dimensional gel electrophoresis) compared with untreated SMCs. When SMCs were cultured in the presence of 10% plasma-derived serum, no proliferation occurred and heparin did not modify alpha-SM actin expression. This suggests that the action of heparin is related to its antiproliferative activity. SMCs cultured in the presence of 10% FCS plus heparin had the same level of proliferation as SMCs cultured in 5% FCS but had a higher content of alpha-SM actin. SMCs cultured in 20% rat whole-blood serum had a proliferation similar to that observed in SMCs cultured in 10% FCS but had a higher content of alpha-SM actin. Moreover, in SMCs cultured in 20% whole-blood serum, heparin inhibited SMC proliferation but did not modify alpha-SM actin expression. Thus, the action of heparin on alpha-SM actin expression appears to be partially independent of proliferation and is related to culture conditions. The proportion of alpha-SM actin mRNA, as measured by Northern blots with an alpha-SM actin mRNA-specific probe, was increased by heparin compared with cells cultured in 10% FCS; this suggests that heparin acts at the transcriptional or posttranscriptional level. Our results show that heparin acts not only on SMC proliferation but also on SMC differentiation; further investigation along these lines may help in the understanding of the mechanisms of SMC adaptation during normal and pathological conditions.
肝素在体内和体外均能抑制动脉平滑肌细胞(SMC)的增殖;此外,它还能在实验性诱导内皮损伤后内膜增厚的SMC中重新诱导α-平滑肌(SM)肌动蛋白(一种公认的SMC分化标志物)的表达。我们研究了肝素对培养的大鼠SMC增殖和肌动蛋白同工型表达的影响。在10%胎牛血清(FCS)存在的情况下,与未处理的SMC相比,经肝素处理的原代和第5代SMC显示增殖减少,α-SM肌动蛋白增加(通过蛋白质免疫印迹法或二维凝胶电泳测定)。当SMC在10%血浆来源血清存在的情况下培养时,未发生增殖,且肝素未改变α-SM肌动蛋白的表达。这表明肝素的作用与其抗增殖活性有关。在10% FCS加肝素存在的情况下培养的SMC与在5% FCS中培养的SMC具有相同的增殖水平,但α-SM肌动蛋白含量更高。在20%大鼠全血血清中培养的SMC与在10% FCS中培养的SMC具有相似的增殖,但α-SM肌动蛋白含量更高。此外,在20%全血血清中培养的SMC中,肝素抑制SMC增殖,但未改变α-SM肌动蛋白的表达。因此,肝素对α-SM肌动蛋白表达的作用似乎部分独立于增殖,且与培养条件有关。用α-SM肌动蛋白mRNA特异性探针通过Northern印迹法测定,与在10% FCS中培养的细胞相比,肝素使α-SM肌动蛋白mRNA的比例增加;这表明肝素在转录或转录后水平起作用。我们的结果表明,肝素不仅作用于SMC增殖,还作用于SMC分化;沿着这些方向的进一步研究可能有助于理解正常和病理条件下SMC适应的机制。